乳腺癌大分割区域淋巴结放疗食管剂量限值及放射性食管炎预测模型的前瞻性验证
该前瞻性队列纳入465例接受43.5 Gy/15次胸壁及区域淋巴结IMRT/VMAT的乳腺癌患者,验证食管RV25<20%和AV35<0.27 mL限值及预测模型。2级放射性食管炎发生率为23.7%,无3级及以上事件;两模型区分度与校准良好,避免不必要内乳淋巴结照射并维持上述限值可降低风险。
要点
- 食管RV25<20%和AV35<0.27 mL限值经前瞻性验证有效。
- 2级放射性食管炎发生率23.7%,无3级及以上事件。
- 左侧肿瘤、内乳淋巴结照射及超限值为风险因素。
核心结论
- 临床验证确认食管剂量限值有效,RV25和AV35模型预测准确。
- 避免不必要的内乳淋巴结照射并维持RV25<20%和AV35<0.27 mL可降低放射性食管炎风险。
研究设计与样本
- 前瞻性队列研究,2022年1月至2024年2月纳入465例乳腺癌患者。
- 患者接受43.5 Gy/15次胸壁及区域淋巴结IMRT/VMAT放疗。
- 食管勾画从环状软骨水平至主动脉弓下缘,放疗期间每周及放疗后1、2周、3、6个月用CTCAE v3.0评估放射性食管炎。
主要发现
- 2级放射性食管炎发生率为23.7%,低于既往报告的40.9%,未观察到3级及以上事件。
- RV25模型AUC为0.688,H-L检验p=0.974;AV35模型AUC为0.651,H-L检验p=0.776。
- 放射性食管炎风险因素包括左侧肿瘤、内乳淋巴结照射以及RV25≥20%或AV35≥0.27 mL。
- 无风险因素为低危,1个风险因素为中危,≥2个风险因素为高危;2级及以上放射性食管炎发生率随风险分组显著升高(RV25模型:14.8% vs 24.7% vs 48.3%;AV35模型:14.7% vs 23.7% vs 45.4%)。
关键数值与推荐
- 食管剂量限值:RV25<20%和AV35<0.27 mL。
- 风险分层:无风险因素为低危,1个风险因素为中危,≥2个风险因素为高危。
临床怎么用
- 乳腺癌区域淋巴结大分割放疗中应评估食管RV25和AV35,并尽量满足限值。
- 避免不必要的内乳淋巴结照射以降低放射性食管炎风险。
- 可利用肿瘤侧别、内乳淋巴结照射及剂量限值进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Esophageal RV25 < 20 % and AV35 < 0.27 mL were reported as dose constraints predictive of grade ≥ 2 radiation esophagitis (RE) for breast cancer in our previous study. This prospective study aimed to validate the effectiveness of esophageal dose constraints and develop RE prediction models. METHODS: We enrolled 465 patients with breast cancer receiving 43.5 Gy in 15 fractions to the chest wall and nodal regions using IMRT/VMAT between January 2022 and February 2024. The esophagus was contoured from the cricoid cartilage level to the aortic arch's lower margin. RE was assessed weekly during radiotherapy and at weeks 1 and 2 and months 3 and 6 post-RT using CTCAE v3.0. Analyzed esophageal dosimetric parameters: total volume, mean/max dose, the relative and absolute volumes receiving at least 5-45 Gy by 5 Gy increments (RV5-RV45 and AV5-AV45). Predictive models incorporating tumor laterality, internal mammary nodal irradiation (IMNI), and RV25 or AV35 thresholds were developed. Discrimination (AUC) and calibration [Hosmer-Lemeshow (H-L) test] were evaluated, and risk stratification was performed using decision tree analysis. RESULTS: The grade 2 RE incidence (23.7 %) was considerably lower than in a previous report (40.9 %), and no grade ≥ 3 RE was observed. Both models performed well (RV25 model: AUC, 0.688, H-L, p = 0.974; AV35 model: AUC, 0.651, H-L, p = 0.776). Risk factors for RE included left-side tumor, IMNI, and RV25 ≥ 20 % or AV35 ≥ 0.27 mL. Patients with no risk factors were classified as low risk, those with one risk factor as intermediate risk, and those with ≥ 2 risk factors as high risk. The grade ≥ 2 RE incidence differed significantly across groups (RV25: 14.8 % vs. 24.7 % vs. 48.3 %; AV35: 14.7 % vs. 23.7 % vs. 45.4 %). CONCLUSION: Clinical validation confirmed the effectiveness of esophageal dose constraints and the predictive accuracy of the RV25 and AV35 models. Avoiding unnecessary IMNI and maintaining RV25 < 20 % and AV35 < 0.27 mL could reduce the risk for RE.
引用
- Wang DQ, Yan L, Wu HF, et al. Prospective cohort study to validate esophageal dose constraints and predictive models for esophagitis in patients with breast cancer undergoing hypofractionated regional nodal radiotherapy. Radiother Oncol. 2025. PMID: 40921329. doi:10.1016/j.radonc.2025.111120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。